Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

Abroad (travel likely)RecruitingPHASE1

Conditions

Healthy Volunteer · Pharmacokinetics · Safety · Drug-Drug Interaction (DDI) · FDC

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

ICON, Clinical Research Phase I Unit, Lenexa, Kansas, United States
Contact: Study coordinator (Daniel Dickerson, MD. PhD, FAAFP) · Daniel.Dickerson@iconplc.com · 913-205-4397
Contact: Principal Investigator (Daniel Dickerson, MD, PhD, FAAFP)

Study leads

Kamal Hamed, MD
Study Director
Basilea Pharmaceutica International Ltd, Allschwil

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)

Pharmacokinetics · Healthy Volunteer

Abroad (travel likely)RecruitingPHASE1

Miami, United States

Analysis of Safety and Tissue Interaction of Injectable Biosmulators

This Study Aims to Evaluate the Safety Profile and Tissue Changes After Biostimulatory Treatments to the Face in Healthy Volunteers

Abroad (travel likely)Recruiting

Hamburg, Germany

Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV913 Capsules

Healthy Volunteers

Abroad (travel likely)RecruitingEARLY_PHASE1

Hefei, China

Study of Food Effects of VV913 Capsules in Chinese Healthy Volunteers

Healthy Volunteers

Abroad (travel likely)RecruitingPHASE1

Hefei, China